Microbot Medical Inc Aktie

Good day, and thank you for standing by. Welcome to Microbot Medical Live Conference Call and Webcast. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Michael Polyviou, Investor Relations. Please go ahead.

Thank you, Dede, and thank you, everyone, for joining us today on Microbot's Medical's conference call and webcast to review 2026 first quarter progress and to provide an update on the latest development.

On the call today from Microbot Medical is Harel Gadot, Chairman, CEO and President; along with Juan Diaz-Cartelle, Chief Medical Officer. Additionally, Dr. Charles Briggs, a vascular surgeon and one of the users of the LIBERTY system at Tampa General Hospital, will share his own experience with the LIBERTY system. Dr. Zachary Bercu, an interventional radiologists with Emory Healthcare and Professor of the Division of Interventional Radiology and Image-Guided Medicine at Emory University School of Medicine and the first user of the LIBERTY system will also join and discuss the experience of utilizing the LIBERTY system in the everyday practice of their interventional radiology department.

This call is also being webcast live over the Internet for all interested parties, and the webcast will be archived in the Investors section of the company's website, www.microbotmedical.com, under Events.

Before turning the call over to Harel, I'd like to make the following remarks concerning forward-looking statements. All statements on this conference call other than historical facts are forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to risks and uncertainties and other factors that may affect Microbot Medical's business, financial condition and other operating results, which include, but are not limited to, the risk factors and other qualifications contained in the company's Form 10-K that was filed with the Securities and Exchange Commission as well as other documents filed with the SEC.

Therefore, actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. Microbot Medical expressly disclaims any intent or obligations to update these forward-looking statements, except as otherwise may be required by applicable law. Statements and opinion provided by guest speakers, including those by Dr. Briggs and Dr. Bercu are theirs, so do not necessarily reflect the opinions or views of Microbot Medical, and the company absolves itself of legal liability for what they say or express.

Finally, after management and guest speakers make their prepared remarks, we will conduct a brief question-and-answer session to be cognizant of the guest speakers' time commitment.

I'd like to turn the call over to Harel. Harel, please go ahead.

Thank you, Michael. And first, I would like to thank all of you who joined us for the call today. For today, I will review recent progress in our status during Q2, and I will then ask our Chief Medical Officer, Juan Diaz-Cartelle, to provide more information on the types of cases to demonstrate the commercial and clinical validation of the LIBERTY Endovascular Robotic System.

We also have 2 esteemed guests on the call, Dr. Zachary Bercu from Emory University from their interventional radiology department who were the first account in the world to adopt the LIBERTY system and Dr. Charles Briggs, a vascular surgeon from Tampa General Hospital in Florida, who was the first vascular surgeons in the world to adopt the LIBERTY Endovascular Robotic System.

In mid-April, as many of you know, we successfully completed our limited market release, and we entered the markets through the phase with [indiscernible]. Revenue midway through the second quarter has already exceeded total first quarter revenue, driven by the number of accounts since the commencement of the full market release, and they have more than doubled. Everything before the full market release were part of our limited market release numbers.

Currently, we have hospitals in 6 states that have adopted the LIBERTY system, including Georgia, Florida, New York, Michigan, Massachusetts and North Carolina. Those are almost all of the territories that we targeted in our limited market release. And as we go into the full market release, we will continue expanding. Earlier this month, Boston became the first city and state in which the company has multiple accounts using the LIBERTY system, and we believe this reflects growing commercial momentum as historically selling into the Boston area, takes more time than in other regions during -- due to longer processes. And for us, within about 4 months to be able to close 2 major accounts in the Boston area, it's a major achievement.

We have seen not only new accounts, but recurrent orders from existing accounts, which reflects their satisfaction with the Liberty system. To remind you, for us to be successful, it's not only selling and opening new accounts. It's the combination of both, continuously increasing our pipeline, getting new accounts and having reorders. We have had success onboarding accounts already in the Southeast, Mid-Atlantic, Northeast, Midwest. This demonstrates that interest from physicians and hassle is translating into new accounts across key sales territories, including 2 of the 3 sites that participated in our ACCESS-PVI pivotal clinical trial, which serves as a strong validation of the added value that it brings. Having accounts that use the product under clinical protocol saw the benefit and turn into commercial adoption, it's a major milestone for us and for any other company.

In addition, we believe that recent adoption by 9 societies of the adoption of guidelines to reduce both radiation exposure and physical strain on the operator will serve as a key catalyzer for growth in the near future. Moreover, the breadth of the procedure that have been performed using the LIBERTY system adds a lot of potential and confidence. We are [indiscernible] we see the [indiscernible] value in the practice in the workflow to adopt it from the interventional radiologists as you're going to hear soon through the vascular surgeons.

To further discuss the breadth of procedures I will ask Juan Diaz-Cartelle, our Chief Medical Officer, to provide more information. Juan, the floor is yours.

Thank you, Harel. Yes. So upon commercialization, the LIBERTY device has been used for a wide variety of procedures. Being the most frequent amongst them prostatic artery embolization or PAE. This is used to treat prostate enlargement. It's estimated at approximately 40 million males in the United States of prostate enlargement that derives into obstruction of the urethra and problems urinating. So this minimally invasive technique is able to treat it without opening the patient.

It is important to note that although for prostatic artery embolization is being performed by interventional radiologists, this technique has been endorsed recently by the American Urological Association, and it's incorporated [indiscernible] LIBERTY in this procedure because it's very anatomically challenging navigating the wires and the micro catheters to get into the correct position takes a very long time. It may take as long as 2 hours or even 3 hours in certain patients that are very complicated to not there. So that's a lot [indiscernible] and also having the ability to control the tools with precision.

Another type of intervention that LIBERTY has been used on is genicular artery embolization, and this is part of a group of procedures in the realm of musculoskeletal artery embolization. So basically, when you have an inflammation of a joint, for example, the knee, this technique serves as a bridge between oral medications and sometimes direct steroid injections in the joint and total knee replacement.

So far, there has been no treatment in between those, either medication or knee replacement, genicular artery embolization offers an option to the patient to significantly reduce the pain for a prolonged period of time, also presents a challenging navigation. That's why the robot here is advantageous in the precision of controlling the wires to get to all the arteries that need to be embolized with this technique. Again, navigation arguably is the longest portion of a procedure where the most [indiscernible] LIBERTY allows you to be away from that radiation point, right? So significantly reducing your exposure.

And another one of the procedures that we've been -- we've seen LIBERTY use on is Y90. This is to treat hepatocellular carcinoma, some types of liver cancer. And it's the infusion of particles covered with a radioactive isotope Yttrium-90. Why does the robot present an advantage here? Because you want very, very little manual manipulation of radioactive components in order to decrease the likelihood of contamination of the personnel or the operating room. And LIBERTY allows you to be completely hands off of these materials in certain portions of the intervention.

So these are the 3 main buckets where LIBERTY has been used, but there has been other users, of course, of LIBERTY.

Thank you, Juan. And this is really reflective on the large usage of LIBERTY already in the market. We have demonstrated by explaining the procedure, the volume in terms of what type of procedure they can do as well as what we see already once we went through the full market relief, the uniqueness of the LIBERTY system, the added value as we'll see in it and are buying it. And as such, we are very encouraged by our progress. I am very confident that our momentum will continue.

To show you our confidence [indiscernible] from the company. Best thing to hear, it's from the users and not only the users, what we would like to do today is give you the first 2 users who had to go through any learning curve. They were the first one to see if there's any issues, if they like it or not, the next 10, the next 20, they already -- lessons learned. But these 2 that I will introduce today can tell you exactly how a new user can feel about it. And I think the best understand how attractive it is and the potential of the LIBERTY Endovascular Robotic System can come from them.

So first, I would like to have Dr. Zachary Bercu, who is an interventional radiology from Emory University to share with you his experience as the first user in the world of using the LIBERTY Endovascular Robotics System. And the importance is to recognize that our main target, our main call point, EDs, the interventional radiologist, Dr. Bercu, if you can take some time, thank you for joining us. And if you can share with the group your experience [indiscernible] LIBERTY Endovascular Robotics System.

Thank you so much, Harel. And thank you, Juan, for that overview. Again, everybody, I'm Zach Bercu, I'm an interventional radiologist at Emory. And I think what we really found from this experience was we -- from all of our conversations that we've had, I'm an academic on a very high level, we believe image-guided Robotics is platform technology that's coming forward. And so it was very exciting for me to be part of doing those initial cases [Audio Gap] huge cumbersome robots that were fixed to room. And all of a sudden, we have this opportunity to use a robot that's small, portable that we're able to open up, decide that we're going to use the case, open it up as if it's just another microcatheter and with a little more than that hook it into the room, hook our microcatheter and microwire. Those are the small tools that we use to navigate that tortuous anatomy that Juan was mentioning earlier. And then basically pick up a controller and start controlling the micro wire and the microcatheter.

This is so portable that if in our busy practice, we have a patient that's on that table that where we did the very last robotic case, it doesn't [indiscernible]. I can take the next robot, go into the other Angio suite and begin to use it for a case. That is not something that ever existed before until this technology came about. So much so that actually we do interventional radiology on 7 different campuses at Emory. And we've already used the robot with different teams of technologists and nurses and interventional radiologists. We've had 4 attendings and 4 trainees, who've been exposed to the robot and using it on 3 different campuses. So very facile and straightforward.

The bulk of procedures that we have done with it are prostate artery embolization, and we do them from a transradial approach. So we'll actually go from the left wrist. So the patient goes home same day after getting the prostate... [Technical Difficulty]

Pardon me, this is your host. Please remain on the line.

Hello, can you all hear me okay?

Dr. Bercu, can you hear us?

Yes. Can you hear me?

Yes. You may proceed.

Okay. Were you able to hear the first part? Or did it cut off?

A couple of times, but most of it we could hear.

Dr. Bercu, we heard all the way to the cases that you're using, and you described the left radial artery.

Thank you so much. And I think the fact that it's portable and disposable is extremely useful. One of the things that's very interesting, and so we did the first prostate artery embolization with the robot. We did the first transradial procedure is we actually had... [Technical Difficulty]

Dr. Bercu, can you hear us?

Can you hear me?

Now we can. You dropped out again.

I'm sorry about that. What I was saying is I disclosed to all patients, use of robotics and use -- just as I do use of AI in different innovative things that we do. And what's interesting is I do that because -- the question is are patients going to be concerned about use of robotics. What we're actually seeing is the opposite.

As soon as there was press about our use of Microbot Liberty at Emory, interestingly, my Division Director, who is covering the same campus I am today has been talking about how patients are actually calling Emory and saying I want the procedure done robotically, that they're seeing this as future forward technology and that they actually are looking for the institutions that deliver that future forward technology.

Anyway, there are a number of different aspects of it that I am happy to talk about in detail, but let me leave it there. I think it's really been an exciting foray and that's not just... [Technical Difficulty]

Pardon me, this is your host. Please remain on the line. Dr. Bercu, can you hear us?

Yes. What did you hear the final portion we had 4 different attendings using it and all had great experience with it as well. So we have been pretty excited about its use here. And I'm happy to answer any questions people have.

Thank you, Dr. Bercu. This is very helpful. With this, if this is okay with you, if you can stay in the line with us, I would like to have Dr. Charles Briggs who was the first vascular surgeon in the world to adopt the LIBERTY Endovascular System [indiscernible] General Hospital. And I would kindly ask Dr. Briggs to share his experience from his which is a very different practice than the IR, but his experience using the LIBERTY Endovascular Robotic System. Dr. Briggs?

Sure. Thank you very much, Harel. I really appreciate the opportunity to discuss my experience with the Liberty Microbot system. I'm a vascular surgeon at University of South Florida, Tampa General Hospital and been in practice now for about 11 years.

My caseload here is largely in the realm of peripheral artery disease, which is obstructions and blockages in the arteries supplying usually the legs, but occasionally other end organ systems. These blockages are usually a composite of calcification and lipid and smooth muscle and can be quite difficult to cross. And as a result, we spend sometimes hours trying to get wires across these blockages from the same side groin or the opposite side femoral artery or the same side tibial vessel at the level of the ankle. And as a result, the radiation can really build up. And so really been looking for a way to reduce my radiation exposure for the last few years.

The other caveat is that you have to wear heavy lead for these, and I found that the last couple of years of my life as I'm in my mid- to late 40s, my back isn't as limber as it used to be, and I find myself throwing out my back a little bit more. So to be able to use the LIBERTY Microbots has really been huge. So it adds no time whatsoever to my case, while I'm advancing the sheath into the position that I wanted my tack or my residents preparing the Microbot, the crosser and after it's installed, I basically sit in the control room with a joystick and cross the lesion, with the 0.014 and 0.018 wire system. And it really saves me in terms of having to wear the heavy lead for hours in a day or spend next to a radiation generator and risk my -- risk of skin cancer or cataracts or skin damage or whatever.

So I found that it's gone very well. I've been successful crossing occlusions 90% of the time and the one that I could not get across actually could not cross by hand either. And so I'll give Microbot a pass on that. But it's been able to cross lesions and the work that we've been doing here has got the attention of some other vascular societies and then we plan to speak to some of those later on this fall. It's very, very, very -- there's quite a lot of excitement about this. It's a very popular concept now, and I've been approached by several calls as well to listen to my experience. And I'd say that it's gone very well, and I'm very happy with it.

Thank you, Dr. Briggs. To summarize what we heard from the physicians is that LIBERTY allows them to stay away from radiation, use the instruments that they need to use to do their procedures. There's no setup time, so it does not interfere with their workflow. Multiple users within the hospitals as we heard that in Tampa, for example, there is both vascular as well as intervention radiology are using it. We heard that at Emory, it's not only 1 hassle, but it's in the system. It's in multiple hospitals.

All of those are fact that are supporting everything that with a company, very transparently communicated to the market since the day we got the FDA clearance. And it was extremely important for us that you will hear it from the users on their experience, not just from us, but as part of our transparency, you can freely listen to them and understand what's happening in the market, how they feel about it. And as you can see already in Q2 that we already more than doubled the accounts that we had in Q1, that we already exceeded the sales already in -- that we had in the entire Q1 that the feedback that we continuously getting on the LIBERTY Endovascular Robotic System is what we expected and beyond.

I'd like to open this call for any questions.

Great. Dede, will you take the queue then?

[Operator Instructions] Our first question comes from Anderson Schock from B. Riley Securities.

So first, from your experience, is the LIBERTY system accommodate guidewires ranging from 0.014-inch to 0.018-inch and the various catheter sizes that you're typically using? And are you at all limited in which procedures you could use the system by its compatibility with the consumables?

If it's okay, I can answer that, and Dr. Briggs, I'd love to hear your viewpoint. But in terms of compatibility, it uses 0.014, 0.018 in any of those micro wires are fine. The microcatheters range from 2.0 French to 3.0 French. That really puts it in the range of the overwhelming majority of micro wires and microcatheters. So the size is not an issue. What we are cognizant of is length. And the only key there is just recognizing that you have enough length for steerability and control of both your microwire and microcatheter. And that's as simple as just having a series of best practices.

So for us, I typically think for prostate, for instance, I typically use a 125-centimeter base catheter. And then I make certain that my microcatheter is an extra 40 to 50 cm and my microwire is extra 40 to 50 cm over the microcatheter. So the typical [indiscernible] and then the microwire would be 220 to 300 cm. And there are plenty of devices, overwhelming number that are all in those ranges.

So I don't know, Dr. Briggs if that's been your experience as well, but I have not found any barriers from that perspective really.

We haven't had any barriers here. There's been no additional capital expense and acquiring new wires and catheters for us, we use 0.014 and 0.018 wires and like you said, 2 and 3 French catheters. Fortunately, there are a number of 2 and 3 French catheters that have the sturdiness to go across these lesions. For me, it's typically a 45-centimeter sheath with a 60-centimeter catheter through it. With the Microbot system loaded on either a 150 cm, 2 or 3 French catheter with 300 length 0.014 or 0.018 wire. And I haven't had any difficulty whatsoever. And like I said, it's been no additional capital expense.

The really nice thing about it is because you know that you -- it actually streamlines the process, you don't have the teammates going room to room looking for various tools. Everything is right there, and it's actually created a maybe even a shortened caseload as opposed to the longer one because of the efficiency.

Okay. Got it. And what is set up time and procedure time looks like when using Liberty compared to the traditional manual approach? Does it add time in the setup of the system? Or does navigating with the system reduce time to reach the target area?

For me, it's net zero as the teammates. My teammates are setting up the Microbot and getting the sheath in place. So I really haven't had any additions to my case time to encase net zero or even that negative.

Yes. I mean that's in my experience as well. Our technologists and nurses have all the best practices that we hook up the side arm pretty quickly. We snap in the micro wire microcatheter. Those -- you're really talking a minute or 2, but then on the flip side, your navigation through tortures anatomy tends to be faster anecdotally. I'll tell you that's been the case. I've had a couple of patients. So when you think about that procedure where we do Y90s. We actually do 2 procedures on a patient. We'll do a mapping first where we map everything out, then we bring them back to usually within about 2 weeks, and then we do an actual Y90 treatment. And I've had a couple of patients where I did one of those not robotically. And then I had the option to use the robot for the actual treatment and it actually got us to the destination faster.

Now that's anecdotal, the academic in me, but the whole -- I mean, in those cases, actually, the procedure time was net zero to slightly decreased as a result of hooking it up and then going right fast to the destination very quickly.

Okay. Got it. And where are you performing these cases? Are you remaining in the room or at the bedside for portions? Or are you mainly operating from a control room behind protective glass?

So most of the procedures that I'm doing right now, I am stepping away from the patient and then kind of getting in a better ergonomic position and controlling the robot. When we -- the procedures right now, just because I'm doing some contrast injections, intraprocedural, I'm walking not too far away from the table. And we -- in our angio suites, we don't yet have remote pedals. Our pedals are still wired, so we're investing in those. But once we have that, it really wouldn't be much barrier to us coming out of the room.

I just find my -- what I tell people is moving to the robot is not going from walking to running. It's going from walking to a bicycle. We're just adapting to a slightly different even though there's a fast learning curve. And so we're creatures of habit. And so getting us to say, hey, wait, you don't have to be sitting in the room, you can get outside of the room. I think it's just going to take us just getting up and walking over there. But already, I'm telling you I'm walking away from... [Technical Difficulty]

Pardon me, this is your host.

Yes, I think we may have lost Dr. Bercu for a moment. If Dr. Briggs wants to answer?

Yes, that's a really great question. So for me for the first few cases, I was in the room separated from the radiation generator by a radiation shield, and I was able to sit on a little stool and drive the robot on the side monitor. There really were no complications, adverse or unexpected problems that rose. And so for the last few, I do leave my scrub -- I usually am scrubbed. I actually go into a sterile empty room and drive the robot away from the radiation generator in the sterile empty room on a monitor. So I've been able to step away, and it's really relieve some of the burden of the radiation.

Okay. And Dr. Briggs, to your knowledge, are there other vascular surgeons in your department using LIBERTY? And outside of that, are there other departments using the system at Tampa General?

Yes. First, there are -- so while I've done in most cases at Tampa General, there are 2 other surgeons that use the LIBERTY system. We have a group of 7 surgeons at Tampa General. So that's nearly half of us who're using the LIBERTY system. There are interventional radiologists as well that use the system. We share an IR suites and those guys are using also. To be fair, we also use the LIBERTY system in the operating room also. So the vascular surgeons are using the LIBERTY system in both the OR and the IR suite and our interventional radiologists are using it in their IR suite as well.

Okay. Were you all able to hear me? Did you hear the full answer. Did it cut out? I'm sorry about the audio issues.

We hear you again, Dr. Bercu

Yes. So I don't know if you all heard that I just felt like ergonomically, I could get into a better position. And we're moving to the point where we need wire-free foot pedal to the controller, I think that will happen pretty quickly once we get that.

Our next question comes from Kyle Bauser of Titan Partners.

Okay. Great. And I appreciate all the updates here. Maybe I'll ask a question to both Dr. Bercu and Dr. Briggs as well. I guess what deciding factors would compel you to pull the LIBERTY off the shelf instead of conducting the procedure manually, I mean, obviously, more difficult cases with torturous anatomy. It helps ergonomically. But I'm trying to understand and get a sense kind of the percentage of cases that the LIBERTY would be preferable over manual.

Yes. When I think about procedures like prostate artery embolization, especially as you talk about people, this is a hot area in interventional radiology because it's an alternative to existing prostate therapies that many patients are seeking alternatives to for a number of different reasons. They don't want TURPs or transurethral. They want something that's the same-day outpatient that doesn't require a catheter in an uncomfortable way through.

And the barrier to these new procedures is experienced in navigating tortuous anatomy. And so I think that having technology that catalyzes that process for many people, we may actually be talking about platform technology that may standardize the procedure. It's interesting to think about. I mean as an academic, that's kind of what I think about may be happening here is I am doing more and more of my PAEs with a robot because I think it's much more facile and easier to get to the destination, and I think it may change the whole procedure as we do it. So not just a fraction looking at imaging beforehand and saying it's tortious but to say that the whole cohort is probably tortuous enough that there's value in considering doing this in most patients. that the ones that it doesn't have value add are probably far and few in between than all those ones where there is a net benefit.

So that's one way we're really thinking about it, in particular with regard to prostate artery embolization. Liver-directed would be more so mapping and Y90 type procedures. I think more about are we treating something that's out deep into the liver versus something that's more proximal in the liver, that may be where more apt to use it. But I think PAE is really something where we're almost looking at a universal-type approach.

This is Dr. Briggs -- Charles Briggs. So there is some overlap with interventional radiology. And so we -- I've used it for difficult arterial embolization, say transmesenteric IMA embolizations for aortic aneurysm endoleak, which is a leak that's developed outside of the stent graft in the treatment of aortic aneurysm. And that's really sort of the Achilles heel of that operation. So these patients undergo lengthy embolization procedures to try to stop the leak around their stent graft. So that's one way in which I've used it.

As the major referral center for a competitive market here in Southwest Florida, we don't see very many patients with mild or minimal atherosclerotic disease. So unfortunately, I'm seeing a lot of SFA -- femoral artery and popliteal artery complete and total occlusion. So if I see someone who has a complete total occlusion, which is fairly frequently, I usually pull the Microbot system. If I think that I can treat them that day, if it's someone who would just benefit from a surgical bypass that I won't pull it. But I really don't do these cases by hand anymore. I basically pull the robot for all of those.

So I'm pulling up for any PAD with a CTO, which is the bulk of what we see at our academic institution here and also for arterial embolizations like Dr. Bercu was saying.

I appreciate that Dr. Briggs. Maybe just a follow-up on that. For CTOs, I mean, is this something where you're deploying and going retrograde? Are you able to approach CTOs in kind of the same manner as manually like in those cases?

Yes, that's another great question. So the first -- very first case I did was actually pedal access tibial CTO, and I was able to hook the robot up from my pedal access sheath, which was a 4 French in the dorsalis pedis artery or just went to tibial artery. So it's not difficult at all to switch the access from femoral to pedal and to switch the robot. The bar is where it is, where the robot is connected to the table. It just take a little bit of adjustment and can access the pedal access sheath rather than the femoral and over the femoral integrated sheath.

So yes, alternating access is wonderful. CTOs are difficult to treat. You can spend hours doing these cases like next to the radiation generator. And so this is something that is near and dear to me is being able to reduce that radiation exposure. And the way that might -- the way to move back from the [indiscernible]. So it's been a revelation here.

Got it. I appreciate that. And then maybe just one more to both doctors. I mean this isn't a traditional robotic system where you've got a big upfront capital outlay that the hospital has to purchase it basically off the shelf and from what I believe is similarly priced to their catheters and guidewires out there. So I guess the question is on cost. You get pushback from hospital administrators or has it been pretty seamless and be able to bring it on?

So for us, it was pretty seamless and straightforward of bring it on. I think because it's such a portable, non-capital budget type device, it was basically like asking for another microcatheter, right, tool or another tool along those lines rather than asking for capital equipment that's in a huge Angio seat. So it goes through a very different pathway. And we explained that this is something that is really facilitating our ability to treat patients with tortuous anatomy, prostate artery embolization. And it need it that it was much easier than, say, if I had asked for a large robot that gets installed into a room, obviously.

The other thing that I think is really interesting that I didn't really think about from the beginning is now patients are actually asking for the place that is doing robotic type procedures. We're starting to see inpatient cohort like that. And there are a couple of other areas where we're seeing that. I mean the academic in me says, okay, but let's go by the science, but we do see that there are patients who are just hearing that it's future forward and they're seeking institutions.

And I think my peers and leaders are taking note of that, that they are excited that we're being sought out because of hey, we're doing this robotically that people are coming and saying, I want to go to the place that's doing this innovative work at a high level to deliver quality to patients.

It was the same here. So we brought this technology to the leadership and leadership absolutely endorsed the purchase. There were no questions asked. It is portable, small. It has intrinsically understandable choice of component. And it's nice that the hospital system would bring this in to relieve some of the burden on the physicians. I mean it's great that the patients can have a shorter case. But for the physicians to be able to be away from the radiation generator and out of lead is really nice. So now there were no barriers to implementation, financial or otherwise here at Tampa General.

Excellent. That's interesting, especially about the patients being able to reach out and promote it as well with Dr. Bercu and Briggs. Thank you so much for taking the time; and Harel, thanks for hosting.

Our next question comes from Yi Chen of H.C. Wainwright & Company.

Dr. Briggs and Dr. Bercu, can you tell us about how many procedures you have performed using LIBERTY so far? Do you feel LIBERTY performs better in one type of procedure than others? And have you already adopted LIBERTY into your routine practice? Or are you still in an evaluation period of the LIBERTY system?

Yes. So it's Dr. Bercu. We have adopted it in a routine practice. We've done 20 cases now, 10 of which were robotic prostate artery embolizations and some of which were other cases, Y90 [indiscernible] artery embolization. I really think, for lack of a better way of putting it I tell people, it's a lot like traveling somewhere from the airport doing these procedures, right? To some extent, the procedure, I'm going to drive to my own local airport, get a plane and fly somewhere. All of that... [Technical Difficulty]

Pardon me, this is your host, Dr. Bercu?

Yes. Sorry. So you land at LaGuardia, and you have to take a trip through the streets of Manhattan to get to the destination, it's extremely cumbersome. The robot facilitates that portion of the journey. And so any procedure that you have a lot of microcatheter work to navigate Tortuosity is going to benefit from robotic control. And so we really think very intentionally about those procedures that are much more surface street travel, a lot of microcatheter navigation versus the plane ride that just gets you to the entryway. And that's been a fundamental paradigm shift in the way that we think about these procedures.

Here at Tampa, I have done 6 cases using the LIBERTY Microbot system. The team understands pretty quickly that if we see a specific constellation of findings on the diagnostic arteriogram, they'll be asking for the microbot system. And so it has culturally become adopted, at least for my cases and some of our partners here. I don't -- I think that I may have answered that question. I don't recall if there's any others, but that's the number. And it has not -- like I said, has not added any time whatsoever. And actually, I think that the resource utilization has come down because we all sort of are on the same page and aligned in what will be pulled and what will be used.

We have exceeded our allotted time. So this concludes our question-and-answer session. I would now like to turn it back to Harel Gadot for closing remarks.

Thank you for everyone for joining us today. We are making solid progress, as you can see, during the full market release of the LIBERTY system which is only in its second month. The team is aggressively pursuing other opportunities, and we look forward to reporting our progress with you in August when we review our Q2 results.

I want to thank Dr. Bercu and Dr. Briggs to openly sharing their experience and answering any of your questions. I want to also thank all the people on this call that asked those questions. In the meantime, thank you for our shareholders for their support, to our team for their dedication and effort, and we wish everyone a good remainder of the day.

Operator, that concludes today's call.

Thank you. That does conclude today's conference call. Thank you for participating, and you may now disconnect.